Illumina Ventures led a $22m Series C round in Arima Genomics.

Illumina Ventures, an independently-managed, healthcare-focused venture firm, led a $22m Series C round in Arima Genomics, a company leveraging whole-genome sequence and structure information to provide comprehensive cancer therapy selection insights, with participation from John Stuelpnagel, Mostafa Ronagh, Co-Win Ventures and Berkeley Catalyst Fund. "During my decade at Illumina Ventures, I evaluated countless genomics innovations, yet Arima’s approach stands out for its ability to illuminate aspects of the genome most tests never see. I am joining from the inside because I believe Arima is uniquely positioned to help save patients’ lives by enabling access to highly effective therapies today and new treatment paradigms going forward," Tom Willis, Arima Genomics CEO.